A Phase 1 Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI7219 in Healthy Subjects, Including Assessment of the Impact of Changes to the Oral Formulation and Determination of Intravenous Pharmacokinetics
Latest Information Update: 28 Mar 2022
At a glance
- Drugs MEDI-7219 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca; MedImmune
- 27 Aug 2020 Status changed from recruiting to discontinued.
- 29 Jun 2020 Planned number of patients changed from 162 to 198.
- 29 May 2020 Status changed from active, no longer recruiting to recruiting.